Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence
- PMID: 27138915
- DOI: 10.1007/s40263-016-0338-3
Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressant medications worldwide. However, over the past decade, their use during pregnancy, a period of extreme vulnerability to the onset of depression, has become highly concerning to patients and their healthcare providers in terms of safety to the developing fetus. Exposure to SSRIs in pregnancy has been associated with miscarriage, premature delivery, neonatal complications, birth defects-specifically cardiac defects-and, more recently, neurodevelopmental disorders in childhood, specifically autism spectrum disorders. Studies addressing the effect of individual SSRIs indicate a small but higher risk for birth defects with maternal fluoxetine and paroxetine use. Though the excess in absolute risk is small, it may still be of concern to some patients. Meanwhile, antenatal depression itself is associated with adverse perinatal outcomes, and discontinuing antidepressant treatment during pregnancy is associated with a high risk of relapse of depression. Whether the observed adverse fetal effects are related to the mother's medication use or her underlying maternal illness remains difficult to determine. It is important that every pregnant woman being treated with an SSRI (or considering such treatment) carefully weighs the risks of treatment against the risk of untreated depression for both herself and her child. The importance of recognizing a higher risk for the development of adverse outcomes lies in the potential for surveillance and possibly a timely intervention. Therefore, we recommend that pregnant women exposed to any SSRI in early pregnancy be offered options for prenatal diagnosis through ultrasound examinations and fetal echocardiography to detect the presence of birth defects. Tapering off or switching to other therapy in early pregnancy, if appropriate for the individual, may also be considered on a case-by-case basis.
Similar articles
-
[Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].Encephale. 2010 Jun;36 Suppl 2:D133-8. doi: 10.1016/j.encep.2009.06.005. Epub 2009 Sep 19. Encephale. 2010. PMID: 20513456 Review. French.
-
Neonatal and childhood neurodevelopmental, health and educational outcomes of children exposed to antidepressants and maternal depression during pregnancy: protocol for a retrospective population-based cohort study using linked administrative data.BMJ Open. 2016 Nov 29;6(11):e013293. doi: 10.1136/bmjopen-2016-013293. BMJ Open. 2016. PMID: 27899401 Free PMC article.
-
Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis.BJOG. 2016 Nov;123(12):1900-1907. doi: 10.1111/1471-0528.14144. Epub 2016 May 30. BJOG. 2016. PMID: 27239775 Free PMC article. Review.
-
Selective Serotonin Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn: An Update Meta-Analysis.J Womens Health (Larchmt). 2019 Mar;28(3):331-338. doi: 10.1089/jwh.2018.7319. Epub 2018 Nov 8. J Womens Health (Larchmt). 2019. PMID: 30407100 Review.
-
[Current evaluation of teratogenic and fetotoxic effects of psychotropic drugs].Seishin Shinkeigaku Zasshi. 2014;116(12):996-1004. Seishin Shinkeigaku Zasshi. 2014. PMID: 25823351 Review. Japanese.
Cited by
-
The antidepressant fluoxetine (Prozac®) modulates serotonin signaling to alter maternal peripartum calcium homeostasis.Sci Rep. 2023 Dec 9;13(1):21832. doi: 10.1038/s41598-023-49253-4. Sci Rep. 2023. PMID: 38071334 Free PMC article.
-
Pharmacokinetics of Antidepressants in Pregnancy.J Clin Pharmacol. 2023 Jun;63 Suppl 1(Suppl 1):S137-S158. doi: 10.1002/jcph.2282. J Clin Pharmacol. 2023. PMID: 37317494 Review.
-
The antidepressant fluoxetine (Prozac®) modulates estrogen signaling in the uterus and alters estrous cycles in mice.Mol Cell Endocrinol. 2023 Jan 1;559:111783. doi: 10.1016/j.mce.2022.111783. Epub 2022 Oct 2. Mol Cell Endocrinol. 2023. PMID: 36198363 Free PMC article.
-
Fluoxetine-induced perinatal morbidity in a sheep model.Front Med (Lausanne). 2022 Aug 4;9:955560. doi: 10.3389/fmed.2022.955560. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35991651 Free PMC article.
-
Fetal Congenital Cardiac and Vascular Disorders Associated with Sertraline Treatment during Pregnancy: Analysis of FAERS Data.Biomed Res Int. 2022 Jul 13;2022:9914931. doi: 10.1155/2022/9914931. eCollection 2022. Biomed Res Int. 2022. PMID: 35872876 Free PMC article. Retracted.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
